The Lack of Antitumor Effects of o,p’DDA Excludes Its Role as an Active Metabolite of Mitotane for Adrenocortical Carcinoma Treatment
Ségolène Hescot . Angelo Paci . Atmane Seck . Abdelhamid Slama . Say Viengchareun . Séverine Trabado . Sylvie Brailly-Tabard . Abir Al Ghuzlan . Jacques Young . Eric Baudin · Marc Lombès
Received: 10 June 2014 / Accepted: 3 July 2014 /Published online: 16 July 2014 C Springer Science+Business Media New York 2014
Abstract Mitotane (o,p’DDD) is the most effective treatment of advanced adrenocortical carcinoma (ACC) but its mecha- nism of action remains unknown. Previous studies suggested that o,p’DDA may represent the active metabolite of mitotane. We aimed at reevaluating the potential role and pharmacolog- ical effects of o,p’DDA. Functional consequences of o,p’DDA exposure were studied on proliferation, steroidogenesis, and mitochondrial respiratory chain in human H295R and SW13 adrenocortical cells. Mitotane and its metabolites were quan- tified using high-performance liquid chromatography com- bined to an ultraviolet detection in these cells treated with o, p’DDD or o,p’DDA and in human adrenal tissues. Dose- response curves up to 300 uM showed that, as opposed to o, p’DDD, o,p’DDA did not inhibit cell proliferation nor alter respiratory chain complex IV activity, gene expression nor induce mitochondrial biogenesis, oxidative stress, or
apoptosis. However, whereas mitotane drastically decreased expression of genes involved in steroidogenesis, o,p’DDA slightly reduced expression of some steroidogenic enzymes and exerts weak anti-secretory effects only at high doses. While o,p’DDD concentration was significantly reduced by 40 % in H295R cell supernatants after 48 h incubation, o,p’ DDA levels remained unchanged suggesting that o,p’DDA was not efficiently transported into the cells. o,p’DDA was not detected in cell homogenates or supernatants after 48 h expo- sure to o,p’DDD, consistent with the absence of o,p’DDA production in these models. Finally, unlike o’p’DDD, we found that o,p’DDA content was undetectable in two ACC and one normal adrenal gland of mitotane-treated patients, suggesting a lack of cellular uptake and in situ production. Our results demonstrate that o,p’DDD, but not o,p’DDA, induces functional alterations in adrenal cells.
Electronic supplementary material The online version of this article (doi:10.1007/s12672-014-0189-7) contains supplementary material, which is available to authorized users.
S. Hescot . S. Viengchareun . S. Trabado . S. Brailly-Tabard · J. Young . E. Baudin . M. Lombès ☒
Inserm U693, Fac Med Paris Sud, 63 rue Gabriel Péri, 94276 Le Kremlin-Bicêtre Cedex, France e-mail: marc.lombes@u-psud.fr
S. Hescot . S. Viengchareun . S. Trabado . S. Brailly-Tabard · J. Young . E. Baudin · M. Lombès Faculté de Médecine Paris-Sud, UMR-S693, Univ Paris-Sud, Le Kremlin-Bicêtre, France
S. Hescot · E. Baudin Department of Nuclear Medicine and Endocrine Tumors, Gustave Roussy Cancer Campus Grand Paris, Villejuif, France
A. Paci · A. Seck Pharmacology and Drug Analysis Department, Gustave Roussy Cancer Campus Grand Paris, Villejuif, France
A. Slama Assistance Publique-Hôpitaux de Paris, Service de Biochimie, CHU Bicêtre, Le Kremlin Bicêtre, France
S. Trabado · S. Brailly-Tabard Assistance Publique-Hôpitaux de Paris, Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, CHU Bicêtre, Le Kremlin Bicêtre, France
A. Al Ghuzlan Department Medical Biology and Pathology, Gustave Roussy Cancer Campus Grand Paris, Villejuif, France
J. Young · M. Lombès Assistance Publique-Hôpitaux de Paris, Service d’Endocrinologie et des Maladies de la Reproduction, CHU Bicêtre, Le Kremlin Bicêtre, France
Introduction
Mitotane (o,p’DDD) represents the most effective drug for the treatment of advanced adrenocortical carcinoma (ACC) and is the only drug approved in the advanced setting [1, 2]. Mitotane is prescribed either in monotherapy or associated with platine-based chemotherapy and induces tumor response rates in up to one third of patients [3]. Recently, the first phase III trial performed in advanced ACC demonstrated that com- bination of mitotane chemotherapy with cisplatine- doxorubicine-etoposide was more effective in prolonging progression-free survival and rate of objective response than the combination of mitotane and streptozotocin [4]. In addi- tion, mitotane is also recommended in the adjuvant setting in ACC patients at high risk of recurrence [5, 6].
However, the mechanism of mitotane action remains to be understood. To date, the only predictive factor of tumor re- sponse is the plasma mitotane level. Indeed, several studies have reported that a higher response rate correlates to plasma mitotane levels above 14 mg/1 [7-11]. Several retrospective studies have also suggested a prolonged survival in case of plasma mitotane levels above 14 mg/l [7, 9, 11] but not all [10, 12]. In addition, as neurological toxicities have been found more frequent with mitotane plasma levels above 20 mg/l [13], the recommended therapeutic window is currently be- tween 14 and 20 mg/l [2].
In a recent study, Hermsen et al. analyzed for the first time the respective role of plasma mitotane level and its metabolites 1,1-(o,p’-dichlorodiphenyl) acetic acid (o,p’DDA) and o,p’ DDE as predictive factors of response in advanced ACC patients. This study concluded that the plasma o,p’DDD level only was associated with tumor response while no major role for its metabolites could be retrieved, questioning the real impact of o,p’DDA as an active metabolite, as previously suggested in preclinical studies.
At the time of ingestion, only 35 % of o,p’DDD is absorbed from the gastrointestinal tract [14] and o,p’DDA has been first described as the main urinary metabolite of o,p’DDD [15, 16]. o,p’DDA is an acid derivative of o,p’DDD, obtained from two consecutive reactions of ß-hydroxylation and dehydrochlori- nation [17]. The site of o,p’DDA synthesis remains unclear in humans. Martz and Straw and later Pohland et al. were able to detect o,p’DDA in hepatic microsomes suggesting an hepatic metabolism of o,p’DDD [18, 19]. Quantitative analyses mea- suring radiolabeled o,p’DDA in various species further re- vealed minute amounts of o,p’DDA in adrenal mitochondria [20-22]. From these initial observations emerged a first hy- pothesis that o,p’DDA could be synthesized in the liver or the adrenals and may represent the active metabolite responsible of the cytotoxic effect observed in the adrenal cortex. Others studies suggested that an adrenal metabolic transformation of o,p’DDD into o,p’DDA could be responsible of the adrenolytic effect [23]. Finally, the question on whether o,p’
DDA is responsible for antitumor effects of mitotane in ACC patients remains totally unanswered.
We have previously described molecular effects of o,p’ DDD on cell proliferation, steroidogenesis, and respiratory chain activity [24]. The aim of the present study was to investigate the exact role of o,p’DDA, in comparison with o, p’DDD. For this purpose, we first explored in vitro molecular effects of o,p’DDA on cell proliferation, mitochondrial respi- ratory chain, and steroidogenesis. We thus studied o,p’DDA conversion and uptake in human adrenocortical H295R and SW13 cell lines and human adrenal tissue samples.
Materials and Methods
Human Adrenocortical Cells and Human Adrenal Tissues
H295R and SW13 cells were cultured in DMEM/HAM’S F-12 medium (PAA, Les Mureaux, France) supplemented with 20 mM HEPES (Life technologies, Saint Aubin, France), antibiotics (penicillin 100 IU/ml, streptomycin 100 µg/ml), and 2 mM glutamine (all from PAA). The medium for H295R cell culture was enriched with 10 % fetal bovine serum and a mixture of insulin/transferrin/selenium. Both cell lines (from passage 2 to 15) were cultured at 37 ℃ in a humidified incubator with 5 % CO2. Mitotane (supplied by HRA Pharma, Paris, France) and o,p’DDA (Alsachim, Illkirch- Graffenstaden, France) were solubilized in dimethyl sulfoxide (DMSO, Sigma-Aldrich, Saint Quentin Fallavier, France) and used at 10 to 300 uM final concentrations. The percentage of DMSO in culture medium never exceeded 0.1 %.
Tissues were obtained from six patients treated with mitotane. Five ACC patients were followed at Gustave Roussy, while patient 1, followed at Bicêtre Hospital, underwent bilateral adrenalectomy for an ectopic Cushing syndrome due a bronchopulmonary ACTH-secreting tumor. All patients signed an informed consent. Tissues were lysed in H2O using a TissueLyser apparatus (Qiagen, Courtaboeuf, France).
Steroid Secretion
Steroid hormones concentrations were measured in the super- natants of H295R cultured cells using radioimmunoassays for 11-deoxycortisol (DiaSource Immunoassays, Louvain-la- Neuve, Belgium) and 17-hydroxyprogesterone (MP Biomedials, Ohio, USA) or chemiluminescent enzyme immu- noassay for cortisol (Immulite 2000 XPI, Siemens Healthcare Diagnostics Products, Llanberis, UK). The intra-assay coeffi- cient of variation (CV) were 5.2 and 7.7 % at 3.7 and 28.3 ng/ml, and the inter-assay CV were 11.5 and 15.1 % at 5.5 and 36.9 ng/ml for 11-deoxycortisol. The intra-assay CV of 17-hydroxyprogesterone radioimmunoassay were 7.8 and
8.3 % at 2.7 and 13.2 ng/ml, respectively, and the inter-assay CV were 9.8 and 12.8 % at 12.3 and 22.8 ng/ml. The intra- assay CV of cortisol assay were 6.1 and 5.2 % at 33 and 85 ng/ml, and the inter-assay CV were 8.2 and 6.8 % at 33 and 85 ng/ml.
Cell Proliferation Analysis
Cell proliferation tests were performed by using the WST1 assay (Roche, Meylan, France) according to the manufac- turer’s recommendations. Cells were cultured in 96-well plates and treated with 10 to 300 uM mitotane or o,p’DDA for 48 h. Optical densities were measured 4 h after addition of WST1 solution (10 ul per well) by spectrophotometry (Viktor, Perkin Elmer, Courtaboeuf, France).
Respiratory Chain Analysis
Respiratory chain activities were measured using spectropho- tometric assays. H295R cells were treated with 50 µM of mitotane (16 mg/l), 50 µM of o,p’DDA (14 mg/l), or vehicle (DMSO) alone for 48 h, and the activity of complex IV (cytochrome c oxidase, COX) was measured in a Cary 50 spectrophotometer, as previously described [24]. The activity of Complex IV was normalized to that of citrate synthase activity, as an index of mitochondrial mass.
Reverse Transcriptase-PCR and Quantitative Real-Time PCR
Total RNAs were extracted from cells with the RNeasy kit (Qiagen, Courtaboeuf, France) according to the manufac- turer’s recommendations. RNA was thereafter processed for reverse transcriptase-PCR (RT-PCR) as previously described [24]. Quantitative real-time PCR (RT-qPCR) was performed using the Fast SYBR® Green Master Mix (Life Technologies) and carried out on a StepOnePlus™M Real-Time PCR System (Life Technologies) as previously described [24]. Standards and samples were amplified in duplicate and analyzed from six independent experiments. The ribosomal 18S rRNA was used as the internal control for data normalization. The relative expression of each gene was expressed as the ratio of attomoles of specific gene to femtomoles of 18S rRNA. The primer sequences of the genes analyzed by qRT-PCR are shown in the Supplemental Table 1.
Western Blot Analysis
Total protein extracts were prepared from cells lysed in lysis buffer (50 mM Tris-HC1, pH 7.5, 150 mM NaCl, 5 mM EDTA, 30 mM Na pyrophosphate, 50 mM Na fluoride, 1 % Triton X-100) and 1X protease inhibitor (Sigma-Aldrich, St. Louis, MO). After protein blotting on an Odyssey nitrocellu- lose membrane (LI-COR, Lincoln, NE, USA), blots were
incubated for 1 h at RT in a blocking buffer (5 % fat-free milk in phosphate-buffered saline (PBS) with 0.1 % Tween 20) before an overnight incubation at 4 ℃ with a rabbit anti-Bcl2 antibody (1:500 dilution, Cell Signaling, Saint Quentin en Yvelines, France) and a mouse anti-«-Tubulin antibody (1:10,000 dilution, Sigma-Aldrich). After extensive washes, blots were incubated with an IRDye 800-conjugated affinity purified anti-rabbit IgG second antibody (1:15,000 dilution, Perbio Science, Brebières, France) and an IRDye 680- conjugated affinity purified anti-mouse IgG second antibody (1:15,000 dilution, Perbio Science) for 1 h at RT. After washes, proteins were visualized with an Odyssey-Fc appara- tus (LI-COR). Specific signals for Bcl2 were normalized by the infrared fluorescence of x-tubulin signals as determined by densitometry using the Image Studio software (LI-COR).
Measurements of o,p’DDD, o,p’DDA, and o,p’DDE Metabolites
Analyses were conducted by high-performance liquid chro- matography combined to an ultraviolet detection (HPLC-UV) on plasma samples of 100 ul spiked with known amounts of p, p’-DDE used as an internal standards (IS) of o,p’-DDD and o, p’-DDE and p.p’-DDA used as an IS of o,p’-DDA measure- ments. o.p’-DDD (mitotane), o,p’-DDA, and o,p’-DDE con- centrations were determined through the ratio of their peak surface area to the peak surface of known concentrations of IS. The method was validated in terms of linearity, precision, and accuracy, with a threshold detection limits of 2.5, 0.1, and 0.25 mg/l for o,p’DDA, o,p’DDE, and o,p’DDD, respectively.
Statistical Analysis
Results are expressed as means+SEM of n independent rep- licates performed in the same experiment or from separated experiments (n). Non parametric Mann-Whitney tests were used when appropriate and differences between groups were analyzed using non parametric Kruskall-Wallis multiple com- parison test followed by a post-test of Dunn’s (Prism software, GraphPad, CA). A P value of 0.05 was considered as statis- tically significant (*P<0.05, ** P<0.01, *** P<0.001).
Results
Comparative Analysis of o,p’DDD and o,p’DDA Impact on Cell Proliferation
We studied the potential anti-proliferative effect of o,p’DDA on H295R and SW13 cells, testing the hypothesis that o,p’ DDA might exert antitumor properties. It is well established that circulating o,p’DDA concentrations are about five times
higher than those of o,p’DDD measured in plasma of patients treated with mitotane [11]. We thus explored functional con- sequences of high doses of o,p’DDA (50 to 300 uM corre- sponding to 14 to 84 mg/l) compared to o,p’DDD on cell proliferation using the colorimetric solution WST1 (Fig. 1). As previously reported, we confirmed that o,p’DDD inhibited proliferation of H295R cells in a dose-dependent manner, with a significant 50 % decrease when cells were exposed to 100 µM for 48 h and a 95 % inhibition when treated with 200 and 300 µM. In sharp contrast, we showed that o,p’DDA, even at the highest concentrations corresponding to its plasma circulating levels in patients, had no significant effect on H295R cell proliferation.
Comparative Effects of o,p’DDD and o,p’DDA on Respiratory Chain Complex IV Activity
We have previously shown that mitotane significantly impaired mitochondrial respiratory chain function by selectively inhibiting enzymatic complex IV activity (cytochrome c oxi- dase, COX) [24]. We thus evaluated the effects of o,p’DDA on COX activity in H295R cells by spectrophotometric assays. COX activity remained unaffected after 48 h exposure to 50 µM of o,p’DDA with a mean activity of 204±13 nmol/min per mg protein, not significantly different from vehicle-treated cells (Fig. 2a). Likewise, activity of citrate synthase (CS), an index of the mitochondrial mass, was not modified in o,p’DDA- treated cells (186±8 nmol/min per mg protein), as compared to vehicle-treated cells (207±6 nmol/min per mg protein). When COX enzymatic activity was normalized to citrate synthase activity (Fig. 2b), o,p’DDA exposure did not modify mitochon- drial respiratory chain activity whereas o,p’DDD significantly reduced COX/CS ratio, as anticipated. We also compared the effect of o,p’DDA and o,p’DDD on the steady-state level of mitochondrial DNA-encoded COX2 transcript (Fig. 2c). While
COX2 expression was significantly reduced by more than 40 % upon o,p’DDD treatment, o,p’DDA failed to modify COX2 mRNA levels. Similar results were obtained with nuclear DNA-encoded COX4 transcripts (data not shown). Taken together, these results clearly demonstrate that o,p’DDA was ineffective in modulating mitochondrial activity.
Consequences of o,p’DDD or o,p’DDA Treatment on Mitochondrial Biogenesis, Oxidative Stress and Apoptosis
In response to mitotane-elicited respiratory chain inhibition, we have previously demonstrated a compensatory increase of mitochondrial biogenesis [24]. We therefore investigated whether or not o,p’DDA was able to induce similar compen- satory mechanisms. Thus, expression of the peroxisome proliferator-activated receptor gamma coactivator 1-related coactivator (PRC), a key regulator of mitochondrial biogene- sis, was quantified by RT-qPCR (Fig. 3a). We showed that o,p’ DDD exposure induces a twofold increase in PRC transcript levels whereas treatment with o,p’DDA has no significant effect of PRC mRNA levels, consistent with the absence of effect on respiratory chain activity described above. We also evaluated consequences of o,p’DDA treatment compared to o, p’DDD on oxidative stress and apoptosis by studying the expression of SOD2 encoding superoxide dismutase 2, an enzyme involved in reactive oxygen species (ROS)-induced detoxification and known to be induced during oxidative stress. Steady-state levels of SOD2 messengers were signifi- cantly increased after incubation with o,p’DDD whereas they remained unchanged with o,p’DDA, suggesting that o,p’DDD but not o,p’DDA induces oxidative stress in H295R cells (Fig. 3b). We found similar results in SW13 (data not shown). At a 50 uM concentration, neither o,p’DDD nor o,p’DDA induces apoptosis as revealed by the anti-apoptotic protein B
Cell proliferation
☒ o,p’DDD
140
☐ o,p’DDA
Absorbance (% DMSO)
120
100
T
80
60
40
20
*
0
10
20
50
100
200
300 μΜ
10
20
50
100
200
300 μΜ
a
Complex IV
Specific activity (nmol/min/mg of protein)
250
200
T
150
100
50
0
DMSO
o,p’DDA
b Complex IV / Citrate synthase
140
*
120
CIVICS (% DMSO)
100
80
60
*
40
20
0
DMSO
o,p’DDD
o,p’DDA
c
COX2
RT-qPCR
**
Relative expression (% DMSO)
120
T
100
T
80
60
T
40
20
0
DMSO
o,p’DDD
o,p’DDA
Fig. 2 Enzymatic activities of complex IV (cytochrome c oxidase, COX) (a) and ratio between complex IV and citrate synthase activities (b) measured in cell homogenates of cells treated for 48 h with 50 µM of o,p’DDD or o,p’DDA. The enzymatic activities were measured using spectrophotometry as described in the “Materials and Methods” section. Results are expressed as nanomole/minute per milligram proteins (a) or as percentage of control ratio arbitrarily set at 100 %. Each experiment was repeated three times. Expression of COX2 (c). H295R cells were treated with 50 LM o,p’DDD or o,p’DDA for 48 h. Relative mRNA expression of each gene was determined using RT-qPCR. Results are means±SEM of six different experiments performed in duplicate and are expressed as percentage of the relative expression in vehicle-treated cells, arbitrarily set at 100 %. o,p’DDA has no effect on respiratory chain activity or gene expression. * P<0.05 and *** P<0.001, Mann-Whitney U test
cell lymphoma 2 (Bcl2) expression using Western blot. How- ever, a drastic reduction of Bcl2 expression was observed with 100 µM mitotane, such reduction was not detected upon o,p’ DDA incubation, suggesting that H295R cells were unaffect- ed by high doses of o,p’DDA (Fig. 3c).
Differential Effects of o,p’DDD and of o,p’DDA on Steroidogenesis
Mitotane might exert dissociated effects with distinct time course patterns, consisting of an early inhibitory effect on steroidogenesis followed by a later cytolytic effect responsible for adrenal cortex atrophy. To explore the impact of o,p’DDA on steroidogenesis, 17-hydroxyprogesterone, deoxycortisol, and cortisol concentrations were measured in the supernatants of steroid-secreting H295R cells. Exposure to 50 uM o,p’ DDA failed to inhibit secretion of 17-hydroxyprogesterone (Fig. 4a) as compared to the 80 % reduction observed follow- ing o,p’DDD incubation. However, when used at higher con- centrations up to 300 µM, o,p’DDA slightly but significantly reduced deoxycortisol and cortisol production without affect- ing 17-hydroxyprogesterone secretion of H295R cells (Fig. 4b). Expression of several genes encoding for proteins involved in steroidogenesis was studied by RT-qPCR (Fig. 4c). While 50 µM mitotane significantly induced a 80 to 95 % decrease of all genes studied, o,p’DDA failed to modify expression of StAR (encoding the transporter of cho- lesterol into mitochondria) or CYP11A1 (encoding cholesterol desmolase) but had negligible effect on HSD3B2 (encoding 3ß-hydroxysteroid dehydrogenase), CYP21 (encoding 21- hydroxylase), and CYP11B1 (encoding 11ß-hydroxylase) consistent with the anti-secretory effects of higher doses of o,p’DDA.
Intracellular Concentrations of o,p’DDD and o,p’DDA in Human Adrenocortical Cells Treated with Mitotane
We next examined the intracellular distribution of these drugs and investigated the ability of human adrenocortical cells to uptake o,p’DDD. We also addressed the question on whether
Fig. 3 Expression of PRC (a) and SOD2 (b). H295R cells were treated with 50 LM o.p’DDD or o, p’DDA for 48 h. Relative mRNA expression of each gene was determined using RT-qPCR. Results are means±SEM of six different experiments performed in duplicate and are expressed as percentage of the relative expression in vehicle-treated cells, arbitrarily set at 100 %. Steady-state levels of Bcl2 protein (anti-apoptotic factor) by Western blot with anti-Bcl2 and anti- tubulin antibodies (c). H295R cells were treated with 50 or 100 LM o,p’DDD or o,p’DDA for 48 h. o.p’DDD is able to increase mitochondrial biogenesis, to induce oxidative stress and apoptosis whereas o,p’DDA fails to exert similar effects. * P<0.05 and *** P<0.001, Mann- Whitney U test
human adrenocortical H295R and SW13 cells were able to actively convert mitotane into o,p’DDA. To explore these possibilities, H295R and SW13 cells were treated with 50 µM of mitotane for 48 h and o,p’DDD and o,p’DDA concentrations were measured in cultured cell supernatants as well as in cell pellets by using HPLC-UV. As shown in Fig. 5a, when H295R cells were exposed to o,p’DDD at a theorical concentration of 50 uM (measured concentration of 54.4±6.2 uM, corresponding to a initial total amount of 325±
a
PRC
RT-qPCR
Relative expression (% DMSO)
250
T
200
150
100
T
50
0
DMSO
o,p’DDD
o,p’DDA
b
SOD2
RT-qPCR
Relative expression (% DMSO)
200
180
T
160
140
120
100
T
T.
80
60
40
20
0
DMSO
o,p’DDD
o,p’DDA
c
o, p’DDD
WB
DMSO
o, p’DDA
MW
55 kDa
a-Tubulin
40 kDa
35 kDa
Bcl2
25 kDa
49 µg), a remaining 31.1±8.7 uM concentration (200±56 µg) was recovered in cell supernatants after 48 h, suggesting an approximately 40 % cellular uptake of o,p’DDD. Accordingly, we were able to measure a total amount of 79±5.1 µg of mitotane in cell pellets (mean±SEM, n=3 indepen- dent experiments) indicating that approximately 25 % of o,p’DDD was actively concentrated into H295R cells while 15 % of initial o,p’DDD was likely deteriorated or bound to the plate as confirmed by a cell-free culture
a
17-hydroxyprogesterone in supernatant
17-hydroxyprogesterone (% DMSO)
160
140
NS
120
T
100
80
60
40
*
20
T
0
DMSO
o,p’DDD
o,p’DDA
b
50 μΜ
120
Steroids in supernatant (% DMSO)
100
T
T
80
T
T
*
T
☒ 17OHP
60
*
T
☐ deoxycortisol
40
☐ cortisol
20
0
o,p’DDA 100 μΜ
o,p’DDA 300 μΜ
c
RT-qPCR
120
Relative expression (% DMSO)
100
☒ o,p’DDD
I
☐ o,p’DDA
80
60
T
T
40
*
20
0
StAR
CYP11A1
HSD3B2
CYP21
CYP11B1
experiment. Similar results were found with SW13 cells (data not shown). Surprisingly, under these experimental conditions, despite a substantial o,p’DDD uptake as
measured above, o,p’DDA concentrations were below limit of quantification (LOQ) threshold in both cell homogenates and cell supernatants, indicating that
a
H295R cell uptake of o,p’DDD
(% of initial concentration)
120
100
T
o,p’DDD
80
**
60
T
*
40
T
20
0
TO
Supernatant
Pellet
T 48h
b
H295R cell supernatant
% of initial supernatant concentration
120
*
100
T
NS
80
**
60
T
40
20
0
TO
o,p’DDD
o,p’DDA
T 48h
H295R cells were unable to convert o,p’DDD into o,p’ DDA and subsequently to secrete the acidic metabolite of mitotane.
Assessment of o,p’DDA Uptake in Human Adrenocortical H295R and SW13 Cells
We next examined the ability of H295R cells to uptake o,p’DDA as compared to o,p’DDD. As shown in Fig. 5b, under experimental conditions in which H295R cells were exposed to 50 µM of o,p’DDA during 48 h, o,p’DDA concentration measured in cell supernatant was not mod- ified (48.75±0.75 µM, mean±SEM of three independent
experiments) and was below LOQ threshold in cell ho- mogenate, suggesting that o,p’DDA was not efficiently transported into H295R cells or was not significantly retained into cell compartment.
o,p’DDD, o,p’DDA, and o,p’DDE Contents in Adrenal Tissues of Mitotane-Treated Patients
In order to examine the tissue distribution of mitotane and its metabolites in humans, six samples of human adrenal tissue from mitotane-treated patients were collected. Patient 1 underwent bilateral adrenalectomy for an ectopic Cushing syndrome due a bronchopulmonary ACTH-secreting tumor whereas patients 2 to 6 had ACC. Cumulative dose of mitotane, duration of treatment, and plasma mitotane levels are reported in Table 1. Patient 2 had a local ACC recurrence with an imaging workup performed 3 months later showing a progressive disease according to RECIST criteria [25]. Thus, he received mitotane for 11 months and the last imaging workup preceding surgery showed a stable disease according to RECIST criteria, defining this patient as responder to mitotane. Patient 3 received mitotane associated with cisplatin and etoposide, his last morphologic work-up before surgery showing a stable disease according to RECIST. Patients 4 and 5 are considered as non responders to mitotane. Indeed, pa- tient 4, presenting with a metastatic ACC, had progressive disease according to RECIST criteria whereas patient 5 pre- sented a local recurrence while he was treated with mitotane as an adjuvant therapy. Finally, evaluation of response to mitotane for patient 6 was not possible since she died shortly after surgery without undergoing imaging work-up. We quan- tified o,p’DDD, o,p’DDA, and o,p’DDE contents in adrenal tissue homogenates measured by HPLC-UV assays (Fig. 6). Results of adrenal gland contents of mitotane and its metab- olites are reported in Table 1. o,p’DDD was found 20- to 40- fold higher in normal adrenal tissue compared to ACC despite lower plasma mitotane level (3.3 mg/l for Cushing’s patient vs 20.03, 18.5, 23.7, 14.7, and 4 mg/l for ACC patients). More importantly, in both ACC and a normal adrenal gland of mitotane-treated patients, o,p’DDA was below LOQ threshold unlike o,p’DDD (Fig. 6).
Discussion
Mitotane remains a major therapeutic option in ACC patients and no new pharmacological strategy has been proposed for the past 30 years [1, 2]. However, only one third of patients are considered as responders and the only predictive factor of response is plasma mitotane level, which has to be between 14 and 20 mg/l, a therapeutic window reached after a mean of 3 months of treatment [8, 26, 27]. For this reason, elucidation of mitotane mechanism of action constitutes a major field of
| Patients (#) | Clinical presentation | Treatment duration (months) | Cumulative dose (g) | Plasma mitotane level (mg/l) | o,p'DDD (µg per 10 mg of tissue) | o,p'DDE (µg per 10 mg of tissue) | o,p'DDA (µg per 10 mg of tissue) |
|---|---|---|---|---|---|---|---|
| 1 | Ectopic Cushing | 5 | 225 | 3.3ª | 17.2 | <LOQ | <LOQ |
| 2 | ACC | 11 | 720 | 20.03b | 0.79 | 0.16 | <LOQ |
| 3 | ACC | 21 | 1470 | 18.5b | 0.21 | <LOQ | <LOQ |
| 4 | ACC | 8 | 765 | 23.7b | 0.44 | 0.11 | <LOQ |
| 5 | ACC | 10 | 870 | 14.7b | 0.65 | <LOQ | <LOQ |
| 6 | ACC | 2 | 180 | 4ª | 4.1 | 0.6 | <LOQ |
An informed consent was obtained for each patient. o,p’DDD and its metabolites were measured in tissue homogenates using HPLC-UV analysis LOQ limit of quantification
a Plasma mitotane level measured 2 weeks before surgery
b Mean of 4 to 15 plasma mitotane levels assessed during treatment
research. Preclinical studies have suggested that o,p’DDA could be the active metabolite of o,p’DDD. The role of o,p’ DDA compound has also been recently reevaluated in ACC patients. In a first study, mean o,p’DDA plasma concentrations measured in mitotane-treated patients were found five times higher than those of o,p’DDD. However, the median time to reach maximal o,p’DDA values was found shorter than for o,p’ DDD (11 vs 55 days, respectively), suggesting that o,p’DDA might constitute an earlier predictor of response [27]. In a second study, o,p’DDA plasma level above 92 mg/l could be more specific than o,p’DDD above 14 mg/l in the prediction of tumor response but its mean level was not correlated with tumor response [11]. Based on the lack of convincing clinical evidence for a major role of o,p’DDA as an active antitumor metabolite of mitotane in ACC patients, we aimed at reevaluating the exact pharmacological contribution of o,p’ DDA by studying its molecular effects in vitro on human adrenocortical H295R and SW13 cells and by investigating its adrenal gland distribution in mitotane-treated patients.
In order to rule out an antitumor role of o,p’DDA, we compared o,p’DDA and o,p’DDD action on cell proliferation, respiratory chain, mitochondrial biogenesis, oxidative stress, apoptosis, and steroidogenesis. To the best of our knowledge, direct functional consequences of o,p’DDA have never been studied before. We first demonstrate that o,p’DDA did not exert any anti-proliferative effect on adrenocortical cells, even at high concentrations up to 300 µM (84 mg/l) corresponding to mean plasma o,p’DDA levels measured in mitotane-treated patients. Second, functional assays showed that low concen- trations such as 50 uM o,p’DDA had no significant impact on mitochondrial respiratory chain activity and biogenesis, and were not able to induce H295R cell oxidative stress or apo- ptosis in sharp contrast to o,p’DDD, as previously described [28, 29].
We quantified for the first time o,p’DDD and its metabo- lites in six human samples of adrenal tissues. Patients rarely
receive mitotane before undergoing surgery that may explain the low number of available samples. We were unable to quantify o,p’DDA metabolite as its concentration was below LOQ, strongly suggesting a lack of in situ production and an absence of uptake of circulating metabolite by adrenal glands. Along this line, o,p’DDA was undetectable in human adreno- cortical H295R or SW13 cell supernatants and pellets after a 48-h exposure with 50 uM mitotane providing additional arguments against an active metabolism of o,p’DDD in human adrenocortical cortex. Further studies should be performed in primary cultures of ACC to confirm the findings of the current study. Previous studies identified o,p’DDA in adrenals of bovines, dogs, or rats treated with radiolabeled mitotane [19-21] but not all [22]. Of note, in these studies, intra- adrenal radiolabeled-o,p’DDA represented less than 5 % of total radioactivity. In contrast, a hepatic production of o,p’ DDA has been previously reported, as demonstrated by met- abolic conversion of o,p’DDD with hepatic microsomes of dogs, rats, or bovines [18, 19]. Similarly, an active hepatic metabolism of o,p’DDD is likely given the mitotane-induced CYP3A4 expression in the liver [30, 31]. Moreover, elevated plasma mitotane levels were found to be associated with a gene polymorphism of CYP2B6 encoding a cytochrome known to catalyze the metabolism of o,p’DDT, structurally close to o,p’DDD [32]. Although our study does not rule out a production of o,p’DDA outside the adrenal gland, likely in liver as previously suggested, our results strongly suggest a lack of capture by adrenal cells and therefore a low if any antitumor activity of o,p’DDA.
We confirmed an uptake of o,p’DDD by H295R cells [29] and demonstrated that up to 25 % of o,p’DDD was measured in cell pellets, suggesting that o,p’DDD itself could be the active compound. Interestingly, we discovered that o,p’DDD content measured into normal human adrenal gland collected after surgery of a mitotane-treated ectopic Cushing patient was much higher than that quantified in five resected ACC, while
a
C
p.p’DDE (IS)
p’,p’DDA (IS)
o,p’DDD
o,p’DDE
o,p’DDA
A
G
3
4
5
6
2
4
Retention time (min)
Retention time (min)
b
d
p,p’DDE (IS)
p’,p’DDA (IS)
o,p’DDA
o,p’DDD
o,p’DDE
£
3
4
5
6
2
4
Retention time (min)
Retention time (min)
plasma circulating mitotane levels were much lower in the former patient compared to the latter (see Table 1). These observations strongly support the notion that the rate of
mitotane uptake in the adrenal gland might be related to the specific transport processes active in normal adrenocortical cells while weakly expressed or absent in ACC. In ACC, o,p’
DDD content was higher in adrenal tissue of the patient presenting with stable disease compared to the adrenal tissues of other patients. However, no conclusion could be drawn from this observation given the small number of samples. Altogether, our experiments bring decisive arguments to ex- clude that o,p’DDA is the active metabolite responsible for adrenolytic effects of mitotane.
In patients, mitotane is known to exert dual effects on adrenal cells including an early inhibition of steroidogenesis and a late destruction of adrenal tissue [33]. Here, o,p’DDA may potentially exert an inhibitory effect of steroidogenesis. Indeed, although o,p’DDA up to 300 µM did not inhibit 17- hydroxyprogesterone secretion, we showed a slight and sig- nificant reduction in the expression of some (HSD3B2, CYP21, and CYP11B1) but not all genes encoding steroido- genic enzymes, consistent with the weak inhibition of cortisol secretion at 300 µM o,p’DDA. Accordingly, it has been re- ported that the aromatic moiety of the o,p’DDD molecule could be responsible for an anti-steroidogenic effect whereas the aliphatic group of this compound could account for its cytolytic effect as previously suggested [34]. Indeed, o,p’ DDD and m,p’DDD which display similar aromatic structures inhibited steroidogenesis while p,p’DDD that exhibits a dif- ferent aromatic cycle was unable to inhibit steroidogenesis [35]. Thus, these findings pointed to the importance of the aliphatic group, notably the dihalogenated methane carbon which is critical for the cytotoxic activity [34], yet lacking in the o,p’DDA structure.
To conclude, our results indicate for the first time an absence of adrenal cell metabolism and uptake of o,p’ DDA and provide in vitro evidence that o,p’DDA is very unlikely an effective metabolite of mitotane to con- trol adrenocortical cell proliferation and to impact mito- chondrial respiratory chain activity. By contrast, we con- firm major interaction of o,p’DDD with adrenal cell functions and proliferation and unambiguously demon- strate a high cellular uptake of o,p’DDD by adrenal cells. Taken together, our results indicate that research on mitotane mechanism of action should focus on o,p’DDD.
Acknowledgments The authors are indebted to HRA Pharma for supporting this research. This work was supported by the Institut National de la Santé et de la Recherche Médicale (Inserm) and Université Paris- Sud. SH is recipient of a fellowship from HRA Pharma Laboratories (Bourse CIFRE).
Conflict of Interest The authors declare that they have no conflict of interest.
References
1. Schteingart DE, Doherty GM, Gauger PG et al (2005) Management of patients with adrenal cancer: recommendations of an international
consensus conference. Endocr Relat Cancer 12:667-680. doi:10. 1677/erc.1.01029
2. Berruti A, Baudin E, Gelderblom H et al (2012) Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol ESMO 23(Suppl 7):vii131-vii138. doi:10.1093/annonc/mds231
3. Baudin E, Leboulleux S, Al Ghuzlan A et al (2011) Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011? Horm Cancer 2:363-371. doi:10.1007/s12672-011- 0094-2
4. Fassnacht M, Terzolo M, Allolio B et al (2012) Combination che- motherapy in advanced adrenocortical carcinoma. N Engl J Med 366: 2189-2197. doi:10.1056/NEJMoa1200966
5. Berruti A, Fassnacht M, Baudin E et al (2010) Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol Off J Am Soc Clin Oncol 28:e401-e402. doi:10. 1200/JCO.2009.27.5958, author reply e403
6. Else T, Williams AR, Sabolch A et al (2014) Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab 99: 455-461. doi:10.1210/jc.2013-2856
7. Haak HR, Hermans J, van de Velde CJ et al (1994) Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69:947-951
8. Baudin E, Pellegriti G, Bonnay M et al (2001) Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p’DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92: 1385-1392
9. Malandrino P, Al Ghuzlan A, Castaing M et al (2010) Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma (ACC). Endocr Relat Cancer. doi:10.1677/ERC-09-0341
10. Wängberg B, Khorram-Manesh A, Jansson S et al (2010) The long- term survival in adrenocortical carcinoma with active surgical man- agement and use of monitored mitotane. Endocr Relat Cancer 17: 265-272. doi:10.1677/ERC-09-0190
11. Hermsen IG, Fassnacht M, Terzolo M et al (2011) Plasma concen- trations of o,p’DDD, o,p’DDA, and o,p’DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retro- spective ENS@T multicenter study. J Clin Endocrinol Metab 96: 1844-1851. doi:10.1210/jc.2010-2676
12. Ayala-Ramirez M, Jasim S, Feng L et al (2013) Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol Eur Fed Endocr Soc 169:891- 899. doi:10.1530/EJE-13-0519
13. Van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D (1984) The treatment of adrenocortical carcinoma with o,p’-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 20:47-53
14. Moy RH (1961) Studies of the pharmacology of o,p’DDD in man. J Lab Clin Med 58:296-304
15. Sinsheimer JE, Guilford J, Bobrin LJ, Schteingart DE (1972) Identification of o,p’-dichlorodiphenyl acetic acid as a urinary me- tabolite of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroeth- ane. J Pharm Sci 61:314-316
16. Reif VD, Sinsheimer JE (1975) Metabolism of 1-(0-chlorophenyl)-1- (p-chlorophenyl)-2,2-dichloroethane (o,p’-DDD) in rats. Drug Metab Dispos Biol Fate Chem 3:15-25
17. Schteingart DE (2007) Adjuvant mitotane therapy of adrenal can- cer-use and controversy. N Engl J Med 356:2415-2418. doi:10. 1056/NEJMe078087
18. Martz F, Straw JA (1980) Metabolism and covalent binding of 1-(o- chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p’,-DDD). Correlation between adrenocorticolytic activity and metabolic acti- vation by adrenocortical mitochondria. Drug Metab Dispos Biol Fate Chem 8:127-130
Springer
19. Pohland RC, Counsell RE (1985) In vitro and in vivo metabolism of a radioiodinated analog of 1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,- dichloroethane. Drug Metab Dispos Biol Fate Chem 13:113-115
20. Martz F, Straw JA (1977) The in vitro metabolism of 1-(o- chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p’-DDD) by dog adrenal mitochondria and metabolite covalent binding to mitochon- drial macromolecules: a possible mechanism for the adrenocorticolytic effect. Drug Metab Dispos Biol Fate Chem 5:482-486
21. Cai W, Benitez R, Counsell RE et al (1995) Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)- 2,2-dichloroethane; o,p’-DDD] and its p,p’- and m,p’-isomers. Biochem Pharmacol 49:1483-1489
22. Cai W, Counsell RE, Djanegara T et al (1995) Metabolic activation and binding of mitotane in adrenal cortex homogenates. J Pharm Sci 84:134-138
23. Cai W, Counsell RE, Schteingart DE et al (1997) Adrenal proteins bound by a reactive intermediate of mitotane. Cancer Chemother Pharmacol 39:537-540
24. Hescot S, Slama A, Lombès A et al (2013) Mitotane alters mitochon- drial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocr Relat Cancer 20:371- 381. doi:10.1530/ERC-12-0368
25. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (ver- sion 1.1). Eur J Cancer Oxf Engl 45:228-247. doi:10.1016/j.ejca. 2008.10.026, 1990
26. Mauclère-Denost S, Leboulleux S, Borget I et al (2012) High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow- up. Eur J Endocrinol Eur Fed Endocr Soc 166:261-268. doi:10.1530/ EJE-11-0557
27. Kerkhofs TM, Baudin E, Terzolo M et al (2013) Comparison of two mitotane starting dose regimens in patients with advanced
adrenocortical carcinoma. J Clin Endocrinol Metab 98:4759-4767. doi:10.1210/jc.2013-2281
28. Lehmann TP, Wrzesiński T, Jagodziński PP (2013) The effect of mitotane on viability, steroidogenesis and gene expression in NCI H295R adrenocortical cells. Mol Med Rep 7:893-900. doi:10. 3892/mmr.2012.1244
29. Poli G, Guasti D, Rapizzi E et al (2013) Morpho-functional effects of mitotane on mitochondria in human adrenocortical cancer cells. Endocr Relat Cancer. doi:10.1530/ERC-13-0150
30. Chortis V, Taylor AE, Schneider P et al (2013) Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5x-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab 98:161-171. doi:10.1210/jc. 2012-2851
31. Takeshita A, Igarashi-Migitaka J, Koibuchi N, Takeuchi Y (2013) Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor. J Endocrinol 216:297-305. doi:10.1530/ JOE-12-0297
32. D’Avolio A, De Francia S, Basile V et al (2013) Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. Pharmacogenet Genomics 23:293-300. doi:10.1097/FPC. 0b013e3283606cb2
33. Bergenstal DM, Dao TLY (1953) Management of Addison’s disease in adrenalectomized patients. Bull N Y Acad Med 29: 295-306
34. Schteingart DE, Sinsheimer JE, Benitez RS et al (2012) Structural requirements for mitotane activity: development of analogs for treatment of adrenal cancer. Anticancer Res 32: 2711-2720
35. Asp V, Cantillana T, Bergman A, Brandt I (2010) Chiral effects in adrenocorticolytic action of o,p’-DDD (mitotane) in human adrenal cells. Xenobiotica Fate Foreign Compd Biol Syst 40:177-183. doi: 10.3109/00498250903470230